Apimeds Pharmaceuticals Inc. (APUS)
AMEX AMEX Primary Summary
Apimeds Pharmaceuticals Inc. (APUS) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Apimeds Pharmaceuticals Inc. ever had a stock split?
Apimeds Pharmaceuticals Inc. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Vinod Menon CEO | AMEX Exchange | 03771D102 CUSIP |
| US Country | 2 Employees | - Last Dividend | 26 Mar 2026 Last Split | - IPO Date |
Overview
Apimeds Pharmaceuticals US, Inc. is a clinical-stage biopharmaceutical company based in Hopewell, New Jersey. Founded in 2020, the company focuses on researching, developing, manufacturing, and commercializing innovative therapeutic solutions. As a subsidiary of Api Meds, Inc., Apimeds is dedicated to advancing pharmaceutical innovations to improve the quality of life for patients suffering from chronic conditions.
The company's primary mission is to address inflammation and pain management symptoms linked to osteoarthritis and multiple sclerosis through its flagship product, Apitox. By utilizing cutting-edge research and development techniques, Apimeds Pharmaceuticals aims to bring effective treatments to market to alleviate patient suffering and enhance their functionality and overall well-being.
Products and Services
- Apitox
Apitox is the company's active pharmaceutical ingredient specifically designed to treat inflammation and manage pain symptoms associated with osteoarthritis and multiple sclerosis. This innovative product seeks to leverage natural compounds known for their therapeutic properties, aiming to provide a safer and more effective treatment alternative for patients.
